INSP analyst estimates
Inspire Medical (INSP) analyst ratings, the average price target and its range, and every firm's latest call.
INSP analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 13, 2026 | Mizuho Securities | Inspire Medical price target raised to $75 from $65 at Mizuho | $75.00 |
| Oct 6, 2026 | Barclays | Inspire Medical initiated with an Underweight at Barclays | $65.00 |
| Oct 1, 2026 | RBC Capital | Inspire Medical price target raised to $75 from $60 at RBC Capital | $75.00 |
| Sep 11, 2026 | Stifel Nicolaus | Inspire Medical price target raised to $80 from $75 at Stifel | $80.00 |
| Aug 4, 2026 | Robert W. Baird | Inspire Medical price target raised to $59 from $54 at Baird | $59.00 |
| Aug 4, 2026 | Piper Sandler | Inspire Medical price target raised to $60 from $55 at Piper Sandler | $60.00 |
| Aug 4, 2026 | Oppenheimer | Inspire Medical upgraded to Outperform from Perform at Oppenheimer | $85.00 |
| Aug 4, 2026 | Stifel Nicolaus | Inspire Medical price target raised to $75 from $65 at Stifel | $75.00 |
| Aug 4, 2026 | RBC Capital | Inspire Medical Systems (INSP) PT Raised to $60 at RBC Capital | $60.00 |
| Aug 4, 2026 | Truist Financial | Inspire Medical price target raised to $62 from $54 at Truist | $62.00 |
| Aug 4, 2026 | Evercore ISI | Inspire Medical price target raised to $54 from $40 at Evercore ISI | $54.00 |
| Jul 28, 2026 | UBS | Inspire Medical assumed with Sell from Neutral at UBS | $39.00 |
| Jul 16, 2026 | Truist Financial | Inspire Medical price target raised to $54 from $50 at Truist | $54.00 |
| Jun 23, 2026 | Evercore ISI | Inspire Medical downgraded to In Line from Outperform at Evercore ISI | $40.00 |
| May 22, 2026 | Summit Redstone Partners | BofA Securities Downgrades Inspire Medical Systems (INSP) to Underperform | $39.00 |
- 16 firms rate INSP: 4 buy, 11 hold, 1 sell.
- The average price target is $63.00 from 11 analysts, from $39.00 to $85.00.
Updated 2026-11-02 23:59 UTC